Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient ...

Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher ...

GAAP revenue surpassed estimates by 24.9% in Q2 2025, driven by milestone payments, including $7 million from Sanofi. Research and development expenses rose 74.0% year-over-year, reflecting higher ...

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and ...

(RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a ...